LLY Eli Lilly and Company
Company Analysis
Latest News
🟢 Eli Lilly is trading 5.34% up today after strong Q2 results and higher 2026 guidance
Eli Lilly is trading 5.34% up now at $1291.24, as investors continue rewarding strong second-quarter results and a higher 2026 revenue outlook. -...
🟢 Eli Lilly is trading 4.5% up today after strong Q2 earnings and raised 2026 guidance
Eli Lilly's stock surged 4.5% to $1287.23 today, driven by continued investor enthusiasm following robust second-quarter earnings where revenue jumped 48%. -...
🟢 Eli Lilly is trading 3.22% up today after Phase III brenipatide depression study registration
Eli Lilly is trading $1221.23 (+3.22%) after registration of a Phase III brenipatide study in adults with depression. • Healthcare is also outperforming, with...
🟢 Eli Lilly is trading 3.1% up today after UK authorizes Foundayo for weight management
Eli Lilly is trading 3.1% up now at $1222.14 after the UK medicines regulator authorized Foundayo for weight management and type 2 diabetes. - The UK is the...
Eli Lilly Wins UK Approval for Foundayo, First Oral GLP-1 in Europe
The UK Medicines and Healthcare products Regulatory Agency (MHRA) authorized Eli Lilly’s (LLY) once-daily pill, Foundayo. Foundayo (orforglipron) treats both...
Lilly's Next-Gen Obesity Drug Gets a Head Start — But Can Retatrutide Justify the Stock's Bounce Before FDA Even Weighs In?
Shares of Eli Lilly surged 5.3% to $1,175 in pre-market trading Thursday, snapping a week-long slide, after the company formalized an expanded early-access...
Lilly's Next-Gen Obesity Drug Gets a Head Start — But Can Retatrutide Justify the Stock's Bounce Before FDA Even Weighs In?
Shares of Eli Lilly surged 5.3% to $1,175 in pre-market trading Thursday, snapping a week-long slide, after the company formalized an expanded early-access...
🟢 Eli Lilly is trading 3.33% up today after Q2 revenue and EPS beat, guidance raised
Eli Lilly is trading 3.33% up now at $1190.00 after its August 5, 2026 earnings report exceeded expectations. - Second-quarter revenue was $22.97 billion and...
🟢 Eli Lilly is trading 7.29% up today on a major revenue guidance hike and GLP-1 strength
Eli Lilly is trading 7.29% up at $1,213.51 following its August 5 earnings report, driven by a significant increase in full-year revenue guidance and continued...
Eli Lilly's second quarter revenue surged 48% to $23.0B, prompting a raised FY26 outlook.
Eli Lilly reported second quarter 2026 revenue of $23.0 billion, up 48% year-over-year, and reported EPS of $7.94. The results were driven by strong demand for...
🟢 Eli Lilly surges 5.3% in pre-market on strong Q2 earnings beat and raised full-year guidance
• Eli Lilly is trading 5.3% up at $1,175.00 in pre-market after reporting second-quarter 2026 financial results that exceeded analyst expectations. • The...
Eli Lilly Opens Early Access to Retatrutide for Severe Obesity Patients
Eli Lilly established an expanded access program for its experimental obesity drug, retatrutide, ahead of potential FDA approval. This program provides the...
Eli Lilly and Company Q2 2026 Earnings Preview: What Analysts Expect on August 05, 2026
Analysts expect Eli Lilly to report Q2 2026 consensus revenue of $20.65 billion and EPS of $6.71, with the current stock price of $1,121.36 sitting below the...
Eli Lilly's Cancer Drug Olomorasib Gets FDA Breakthrough Therapy Tag for Pancreatic Cancer
Eli Lilly and Company announced its experimental drug, olomorasib, received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA)....
🔴 Eli Lilly is trading 3% down today on profit-taking after a multi-month rally and sector volatility
Eli Lilly is trading 3% down at $1114.17 on profit-taking and consolidation following a strong multi-month rally and recent sector-wide volatility. • The move...
🔴 Eli Lilly is trading 3.4% down today as managed care weakness weighs on sector sentiment
Eli Lilly is trading 3.4% down at $1,165.73 as managed care weakness drags the broader healthcare sector lower. • The move occurs without fresh...
Eli Lilly and Resilience to Invest $750 Million in U.S. Manufacturing Expansion
Eli Lilly and Company, with contract manufacturer Resilience, announced a $750 million investment. This investment will expand pharmaceutical production in the...
Eli Lilly Retatrutide Succeeds in Phase 3, Showing 22.6% Weight Loss
Eli Lilly and Company reported positive topline results from its TRIUMPH-2 and TRIUMPH-3 Phase 3 trials for retatrutide. The investigational weight-loss drug...
Novo Nordisk sues Eli Lilly, alleging false ads for Zepbound and Mounjaro
Novo Nordisk filed a lawsuit in U.S. federal court against Eli Lilly for false and misleading advertising. The complaint targets marketing for Lilly’s...
Eli Lilly's Foundayo prescriptions jump to 24,303, defying broader market slump
Weekly prescriptions for Eli Lilly’s oral obesity drug Foundayo reached 24,303. This figure breaks a five-week plateau where prescriptions remained near...